1368488
2019
1
heidelberg-university-faculty-of-medicine
50
creator
asc
year
1
190
https://cnrmyrma.fr/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22SIQ2GJB4%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Andr%5Cu00e9s%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAndr%26%23xE9%3Bs%2C%20M.%2C%20Werf%2C%20M.%20J.%20van%20der%2C%20K%26%23xF6%3Bdm%26%23xF6%3Bn%2C%20C.%2C%20Albrecht%2C%20S.%2C%20Haas%2C%20W.%2C%20Fiebig%2C%20L.%20and%20Group%2C%20S.%20study%20%282019%29.%20%3Cb%3EMolecular%20and%20genomic%20typing%20for%20tuberculosis%20surveillance%3A%20A%20survey%20study%20in%2026%20European%20countries%3C%5C%2Fb%3E.%20PLOS%20ONE%20%3Ci%3E14%3C%5C%2Fi%3E%2C%20e0210080%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0210080%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0210080%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20and%20genomic%20typing%20for%20tuberculosis%20surveillance%3A%20A%20survey%20study%20in%2026%20European%20countries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marta%22%2C%22lastName%22%3A%22Andr%5Cu00e9s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marieke%20J.%20van%20der%22%2C%22lastName%22%3A%22Werf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Csaba%22%2C%22lastName%22%3A%22K%5Cu00f6dm%5Cu00f6n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stefan%22%2C%22lastName%22%3A%22Albrecht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Walter%22%2C%22lastName%22%3A%22Haas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lena%22%2C%22lastName%22%3A%22Fiebig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Survey%20study%22%2C%22lastName%22%3A%22Group%22%7D%5D%2C%22abstractNote%22%3A%22Background%20Molecular%20typing%20and%20whole%20genome%20sequencing%20%28WGS%29%20information%20is%20used%20for%20%28inter-%29%20national%20outbreak%20investigations.%20To%20assist%20the%20implementation%20of%20these%20techniques%20for%20tuberculosis%20%28TB%29%20surveillance%20and%20outbreak%20investigations%20at%20European%20level%20there%20is%20a%20need%20for%20inter-country%20collaboration%20and%20standardization.%20This%20demands%20more%20information%20on%20molecular%20typing%20practices%20and%20capabilities%20of%20individual%20countries.%20We%20aimed%20to%20review%20the%20use%20of%20molecular%5C%2Fgenomic%20typing%20for%20TB%20surveillance%20in%20European%20Union%20and%20European%20Economic%20Area%20countries%20in%202016%3B%20assess%20its%20public%20health%20value%3B%20and%20collect%20experiences%20on%20typing%20data%20use%20for%20cross-border%20cluster%20investigations.%20Method%20A%20web-based%20questionnaire%20was%20provided%20to%20all%20TB%20National%20Focal%20Points.%20The%20questionnaire%20consisted%20of%20three%20parts%3A%20i%29%20Use%20and%20integration%20of%20molecular%20and%20genomic%20typing%20data%20into%20TB%20surveillance%3B%20ii%29%20Cross-border%20cluster%20investigation%20and%20international%20collaboration%2C%20and%20iii%29%20Perception%20and%20evaluation%20of%20public%20health%20benefits%20of%20molecular%20and%20genomic%20typing%20for%20TB%20surveillance.%20Results%20Of%2026%20responding%20countries%2C%2020%20used%20molecular%20typing%20for%20TB%20surveillance%2C%20including%20nine%20applying%20WGS.%20The%20level%20of%20integration%20into%20the%20national%20surveillance%20was%20heterogeneous.%20Among%20six%20countries%20not%20using%20typing%20for%20TB%20surveillance%2C%20more%20than%20half%20planned%20its%20implementation%20soon.%20Overall%2C%20most%20countries%20perceived%20an%20added%20public%20health%20value%20of%20molecular%20typing%20for%20TB%20control.%20Concerning%20international%20cluster%20investigations%2C%20countries%20had%20little%20experience%20and%20did%20not%20have%20standard%20protocols%20to%20exchange%20typing%20data.%20Conclusion%20Our%20study%20shows%20a%20wide%20use%20of%20molecular%20and%20genomic%20typing%20data%20for%20TB%20surveillance%20in%20EU%5C%2FEEA%20countries%20and%20reveals%20that%20transition%20to%20WGS-based%20typing%20is%20ongoing%20or%20is%20considered%20in%20most%20countries.%20However%2C%20our%20results%20also%20show%20a%20high%20heterogeneity%20in%20the%20use%20and%20integration%20of%20typing%20data%20for%20TB%20surveillance.%20Standardization%20of%20typing%20data%20use%20for%20TB%20surveillance%20is%20needed%20and%20formal%20procedures%20should%20be%20developed%20to%20facilitate%20international%20collaboration.%22%2C%22date%22%3A%2213%20mars%202019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0210080%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournals.plos.org%5C%2Fplosone%5C%2Farticle%3Fid%3D10.1371%5C%2Fjournal.pone.0210080%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A58%3A55Z%22%7D%7D%2C%7B%22key%22%3A%22VBBUA2T8%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Aubry%20and%20Veziris%22%2C%22parsedDate%22%3A%222019-10-15%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EAubry%2C%20A.%20and%20Veziris%2C%20N.%20%282019%29.%20%3Cb%3ESmear%20Microscopy%20Complements%20Xpert%20MTB%5C%2FRIF%20When%20Considering%20Nontuberculous%20Mycobacterial%20Infections%3C%5C%2Fb%3E.%20Am%20J%20Respir%20Crit%20Care%20Med%20%3Ci%3E200%3C%5C%2Fi%3E%2C%201072%26%23x2013%3B1073%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.201905-0965LE%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1164%5C%2Frccm.201905-0965LE%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Smear%20Microscopy%20Complements%20Xpert%20MTB%5C%2FRIF%20When%20Considering%20Nontuberculous%20Mycobacterial%20Infections%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222019-10-15%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1164%5C%2Frccm.201905-0965LE%22%2C%22ISSN%22%3A%221073-449X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.atsjournals.org%5C%2Fdoi%5C%2F10.1164%5C%2Frccm.201905-0965LE%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A56%3A07Z%22%7D%7D%2C%7B%22key%22%3A%2223X4SDIJ%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Baron%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBaron%2C%20V.%2C%20Forfait%2C%20C.%2C%20Colot%2C%20J.%2C%20Carzola%2C%20C.%2C%20Descloux%2C%20E.%2C%20Cauchoix%2C%20B.%2C%20Cambau%2C%20E.%2C%20Gaumery%2C%20J.%2C%20Grangeon%2C%20J.%20and%20Klement%2C%20E.%20%282019%29.%20%3Cb%3E%26%23xC9%3Bpid%26%23xE9%3Bmiologie%20de%20la%20l%26%23xE8%3Bpre%20en%20Nouvelle-Cal%26%23xE9%3Bdonie%20de%201983%20%26%23xE0%3B%202017%3C%5C%2Fb%3E.%20BEH%20400%26%23x2013%3B405%2C%20URL%3A%20%3Ca%20target%3D%27_blank%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.santepubliquefrance.fr%5C%2Fimport%5C%2Fepidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017%27%3Ehttps%3A%5C%2F%5C%2Fwww.santepubliquefrance.fr%5C%2Fimport%5C%2Fepidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017%3C%5C%2Fa%3E%20%5BAccessed%20February%202022%5D.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5Cu00c9pid%5Cu00e9miologie%20de%20la%20l%5Cu00e8pre%20en%20Nouvelle-Cal%5Cu00e9donie%20de%201983%20%5Cu00e0%202017%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Violaine%22%2C%22lastName%22%3A%22Baron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Forfait%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%22%2C%22lastName%22%3A%22Colot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Carzola%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Descloux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%22%2C%22lastName%22%3A%22Cauchoix%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22JB%22%2C%22lastName%22%3A%22Gaumery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22JP%22%2C%22lastName%22%3A%22Grangeon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Klement%22%7D%5D%2C%22abstractNote%22%3A%22%5Cu00c9pid%5Cu00e9miologie%20de%20la%20l%5Cu00e8pre%20en%20Nouvelle-Cal%5Cu00e9donie%5Cnde%201983%20%5Cu00e0%202017%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22fr%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.santepubliquefrance.fr%5C%2Fimport%5C%2Fepidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-06-03T06%3A54%3A59Z%22%7D%7D%2C%7B%22key%22%3A%228TSRPDWW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bouziane%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBouziane%2C%20F.%2C%20Allem%2C%20R.%2C%20Sebaihia%2C%20M.%2C%20Kumanski%2C%20S.%2C%20Mougari%2C%20F.%2C%20Sougakoff%2C%20W.%2C%20Raskine%2C%20L.%2C%20Yala%2C%20D.%20and%20Cambau%2C%20E.%20%282019%29.%20%3Cb%3EFirst%20genetic%20characterisation%20of%20multidrug-resistant%20Mycobacterium%20tuberculosis%20isolates%20from%20Algeria%3C%5C%2Fb%3E.%20Journal%20of%20Global%20Antimicrobial%20Resistance%20%3Ci%3E19%3C%5C%2Fi%3E%2C%20301%26%23x2013%3B307%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jgar.2019.05.010%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jgar.2019.05.010%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22First%20genetic%20characterisation%20of%20multidrug-resistant%20Mycobacterium%20tuberculosis%20isolates%20from%20Algeria%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Feriel%22%2C%22lastName%22%3A%22Bouziane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachida%22%2C%22lastName%22%3A%22Allem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohammed%22%2C%22lastName%22%3A%22Sebaihia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Kumanski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Djamel%22%2C%22lastName%22%3A%22Yala%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%5D%2C%22abstractNote%22%3A%22Objectives%5CnTo%20characterise%20the%20genotypes%20of%20multidrug-resistant%20%28MDR%29%20Mycobacterium%20tuberculosis%20%28MTB%29%20isolated%20in%20Algeria%2C%20where%20there%20is%20a%20low%20MDR-MTB%20incidence%20rate.%5CnMethods%5CnTen%20MDR%20isolates%20and%20one%20resistant%20to%20isoniazid%20were%20investigated%20by%20PCR-Sanger%20sequencing%20for%2010%20loci%20involved%20in%20resistance.%20Amplicon-based%20next%20generation%20sequencing%20%28NGS%29%20of%2015%20loci%20was%20additionally%20performed%20on%20isolates%20harbouring%20novel%20mutations.%5CnResults%5CnSanger%20and%20amplicon-NGS%20provided%20the%20same%20results%20as%20with%20GenoType%20kits.%20Mutations%20known%20to%20be%20associated%20with%20resistance%20were%20described%20for%20most%20isolates%3A%20rpoB%20S531L%20in%20seven%20of%2010%20rifampicin-R%20MTB%20isolates%2C%20katG%20S315T%20in%20nine%20of%2011%20isoniazid-R%2C%20and%20promoter%20inhA%20c-15t%20in%20three%20of%2011%2C%20embB%20M306V%20or%20M306I%20in%20two%20of%20two%20ethambutol-R%2C%20rpsL%20K43R%20in%20four%20of%20eight%20or%20rrs%20a514c%20associated%20with%20gidB%20L16R%20in%20streptomycin-R%2C%20gyrA%20A90V%20in%20the%20ofloxacin-R%20pre-XDR%20isolate.%20New%20and%20rare%20mutations%20were%20also%20described%20in%20rpoB%20%28deletion%20512-513-514%29%2C%20katG%20%28S315R%2C%20M126I%5C%2F%20R496L%29%2C%20gidB%20%28V124G%2C%20E92A%2C%20V139A%2C%20G37V%29%2C%20and%20gyrA%20%28P8A%29.%20Mycobacterial%20interspersed%20repetitive-unit-variable-number%20tandem-repeat%20%28MIRU-VNTR%29%20profiles%20were%20similar%20for%20three%20isolates%20%28lineage%20Cameroon%29%2C%20indicating%20a%20possible%20clonal%20diffusion%20in%20epidemiologically%20unrelated%20patients.%5CnConclusions%5CnResistant%20MTB%20isolates%20in%20Algeria%20harbour%20resistance%20genotypes%20similar%20to%20other%20countries%2C%20but%20some%20rare%20patterns%20may%20result%20from%20selection%20and%20transmission%20processes%20inherent%20to%20the%20country.%22%2C%22date%22%3A%22d%5Cu00e9cembre%201%2C%202019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jgar.2019.05.010%22%2C%22ISSN%22%3A%222213-7165%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS2213716519301201%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A59%3A46Z%22%7D%7D%2C%7B%22key%22%3A%226A2DEBBX%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Daniau%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDaniau%2C%20C.%2C%20Lecorch%26%23xE9%3B%2C%20E.%2C%20Mougari%2C%20F.%20and%20et%20al.%20%282019%29.%20%3Cb%3EInfections%20invasives%20%26%23xE0%3B%20Mycobacterium%20chimaera%20en%20chirurgie%20cardiaque%20et%20%26%23xE9%3Bvaluation%20des%20pratiques%20autour%20des%20mat%26%23xE9%3Briels%20de%20circulation%20extracorporelle%3C%5C%2Fb%3E.%20Hygienes%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20351%26%23x2013%3B359%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.25329%5C%2Fhy_xxvii_6-1%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.25329%5C%2Fhy_xxvii_6-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Infections%20invasives%20%5Cu00e0%20Mycobacterium%20chimaera%20en%20chirurgie%20cardiaque%20et%20%5Cu00e9valuation%20des%20pratiques%20autour%20des%20mat%5Cu00e9riels%20de%20circulation%20extracorporelle%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%22%2C%22lastName%22%3A%22Daniau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E%22%2C%22lastName%22%3A%22Lecorch%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22%22%2C%22lastName%22%3A%22et%20al.%22%7D%5D%2C%22abstractNote%22%3A%22%3Cp%20class%3D%5C%22Resume_F%5C%22%3E%3Cstrong%20class%3D%5C%22F_Resume_bold%5C%22%3EObjectif.%5Cu00a0%3C%5C%2Fstrong%3ESuite%20aux%20deux%20cas%20confirm%5Cu00e9s%20d%5Cu2019infection%20%5Cu00e0%5Cu00a0%3Cem%3EMycobacterium%20chimaera%3C%5C%2Fem%3E%5Cu00a0identifi%5Cu00e9s%20en%202015%2C%20une%20recherche%20r%5Cu00e9trospective%20de%20cas%20apr%5Cu00e8s%20un%20acte%20de%20chirurgie%20cardiaque%20sous%20circulation%20extracorporelle%20%28CEC%29%20et%20une%20enqu%5Cu00eate%20sur%20les%20pratiques%20li%5Cu00e9es%20aux%20mat%5Cu00e9riels%20de%20CEC%20en%20France%20ont%20%5Cu00e9t%5Cu00e9%20mises%20en%20%5Cu0153uvre.%5Cu00a0%3Cstrong%20class%3D%5C%22F_Resume_bold%5C%22%3EM%5Cu00e9thode.%5Cu00a0%3C%5C%2Fstrong%3EL%5Cu2019enqu%5Cu00eate%20a%20cibl%5Cu00e9%20les%20%5Cu00e9tablissements%20de%20sant%5Cu00e9%20%28ES%29%20qui%20pratiquent%20des%20actes%20de%20chirurgie%20cardiaque%20sous%20CEC%20en%20France.%20Les%20informations%20recueillies%20par%20questionnaire%20portaient%20sur%20la%20p%5Cu00e9riode%20du%201%3Cspan%20class%3D%5C%22supp%20_idGenCharOverride-1%5C%22%3Eer%3C%5C%2Fspan%3E%5Cu00a0janvier%202015%20au%2031%5Cu00a0juin%202017.%5Cu00a0%3Cstrong%20class%3D%5C%22F_Resume_bold%5C%22%3ER%5Cu00e9sultats.%5Cu00a0%3C%5C%2Fstrong%3EParmi%20les%2061%20services%20de%20chirurgie%20cardiaque%20sollicit%5Cu00e9s%2C%2056%20%2892%25%29%20ont%20particip%5Cu00e9%20%5Cu00e0%20l%5Cu2019enqu%5Cu00eate.%20Aucun%20%5Cu00e9tablissement%20n%5Cu2019a%20d%5Cu00e9clar%5Cu00e9%20de%20cas%20d%5Cu2019infection%20invasive%20%5Cu00e0%5Cu00a0%3Cem%3EM.%5Cu00a0chimaera%3C%5C%2Fem%3E%5Cu00a0depuis%202015.%20L%5Cu2019utilisation%2C%20pour%20la%20CEC%2C%20de%20227%20g%5Cu00e9n%5Cu00e9rateurs%20thermiques%20%28GT%29%20a%20%5Cu00e9t%5Cu00e9%20d%5Cu00e9clar%5Cu00e9e%20par%20les%20ES%20participants%2C%20soit%205%2C8%20GT%20pour%201%20000%20interventions%20par%20an.%20Les%20recommandations%20des%20fabricants%20relatives%20%5Cu00e0%20l%5Cu2019entretien%20des%20GT%20%5Cu00e9taient%20appliqu%5Cu00e9es%20par%20une%20minorit%5Cu00e9%20d%5Cu2019%5Cu00e9tablissements%20%287%25%29.%20Les%20contr%5Cu00f4les%20microbiologiques%20de%20l%5Cu2019eau%20des%20GT%20ont%20montr%5Cu00e9%20que%2056%25%20d%5Cu2019entre%20eux%20%5Cu00e9taient%20contamin%5Cu00e9s%20par%20des%20bact%5Cu00e9ries%20usuelles%20et%2023%25%20par%20des%20mycobact%5Cu00e9ries%20du%20complexe%5Cu00a0%3Cem%3EMycobacterium%20avium.%3C%5C%2Fem%3E%5Cu00a0%3Cstrong%20class%3D%5C%22F_Resume_bold%5C%22%3EConclusion.%3C%5C%2Fstrong%3E%5Cu00a0Les%20ES%20n%5Cu2019ont%20pas%20identifi%5Cu00e9%20de%20nouveau%20cas%20d%5Cu2019infection%20%5Cu00e0%5Cu00a0%3Cem%3EM.%5Cu00a0chimaera%3C%5C%2Fem%3E%5Cu00a0mais%20la%20contamination%20des%20GT%20%5Cu00e9tait%20importante.%20Les%20difficult%5Cu00e9s%20rencontr%5Cu00e9es%20par%20les%20ES%20dans%20la%20mise%20en%20%5Cu0153uvre%20des%20recommandations%20des%20fabricants%20pour%20l%5Cu2019entretien%20et%20le%20contr%5Cu00f4le%20microbiologique%20des%20GT%20sugg%5Cu00e8rent%20la%20n%5Cu00e9cessit%5Cu00e9%20de%20recommandations%20nationales%20pour%20am%5Cu00e9liorer%20les%20pratiques%20d%5Cu2019entretien%20des%20mat%5Cu00e9riels%20de%20CEC.%3C%5C%2Fp%3E%22%2C%22date%22%3A%222019-06-01%22%2C%22language%22%3A%22fr-FR%22%2C%22DOI%22%3A%2210.25329%5C%2Fhy_xxvii_6-1%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.hygienes.net%5C%2Fboutique%5C%2Fhygienes-2%5C%2Finfections-invasives-a-mycobacterium-chimaera-en-chirurgie-cardiaque-et-evaluation-des-pratiques-autour-des-materiels-de-circulation-extracorporelle%5C%2F%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-12T08%3A24%3A20Z%22%7D%7D%2C%7B%22key%22%3A%22JINIH26W%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Decalonne%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDecalonne%2C%20M.%2C%20Lecorche%2C%20E.%2C%20Hau%2C%20E.%2C%20Petiteau%2C%20A.%2C%20Moreau%2C%20C.%2C%20Milan%2C%20O.%2C%20Lanotte%2C%20P.%2C%20Mereghetti%2C%20L.%2C%20Cambau%2C%20E.%20and%20van%20der%20Mee-Marquet%2C%20N.%20%282019%29.%20%3Cb%3ECause%20Analysis%20of%20an%20Infection%20in%20Facelift%20Surgery%20Due%20to%20Mycobacterium%20chelonae%3C%5C%2Fb%3E.%20Frontiers%20in%20Medicine%20%3Ci%3E6%3C%5C%2Fi%3E%2C%20URL%3A%20%3Ca%20target%3D%27_blank%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticle%5C%2F10.3389%5C%2Ffmed.2019.00243%27%3Ehttps%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticle%5C%2F10.3389%5C%2Ffmed.2019.00243%3C%5C%2Fa%3E%20%5BAccessed%20February%202022%5D.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Cause%20Analysis%20of%20an%20Infection%20in%20Facelift%20Surgery%20Due%20to%20Mycobacterium%20chelonae%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Decalonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Lecorche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Hau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Petiteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lia%22%2C%22lastName%22%3A%22Moreau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Milan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philipe%22%2C%22lastName%22%3A%22Lanotte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Mereghetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Cambau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22van%20der%20Mee-Marquet%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20a%20post-facelift%20infection%20due%20to%20Mycobacterium%20chelonae.%20An%20environmental%20strain%20recovered%20from%20the%20water%20supply%20network%20of%20the%20surgical%20clinic%20and%20the%20clinical%20strains%20were%20considered%20non-differentiable%20using%20whole%20genome%20sequencing.%20After%20the%20unhealed%20wound%27s%20exposure%20to%20M.%20chelonae%20while%20showering%20early%20at%20the%20clinic%20after%20surgery%2C%20a%20lasting%20exposure%20of%20the%20colonized%20wound%20to%20the%20warm%20and%20moist%20working%20conditions%20of%20a%20bakery%20may%20have%20been%20favorable%20to%20the%20infection%27s%20development.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%22%22%2C%22ISSN%22%3A%222296-858X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticle%5C%2F10.3389%5C%2Ffmed.2019.00243%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A52%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22MTVU5FER%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dutertre%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDutertre%2C%20M.%2C%20Delobel%2C%20P.%2C%20Marchou%2C%20B.%2C%20Boyer%2C%20J.-F.%2C%20Mougari%2C%20F.%20and%20Martin-Blondel%2C%20G.%20%282019%29.%20%3Cb%3EOlecranon%20bursitis%20secondary%20to%20Mycobacterium%20europaeum%20infection%20in%20a%20patient%20receiving%20immunosuppressive%20drugs%20for%20rheumatoid%20arthritis%3C%5C%2Fb%3E.%20M%26%23xE9%3Bdecine%20et%20Maladies%20Infectieuses%20%3Ci%3E49%3C%5C%2Fi%3E%2C%20358%26%23x2013%3B359%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2019.03.002%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.medmal.2019.03.002%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Olecranon%20bursitis%20secondary%20to%20Mycobacterium%20europaeum%20infection%20in%20a%20patient%20receiving%20immunosuppressive%20drugs%20for%20rheumatoid%20arthritis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marine%22%2C%22lastName%22%3A%22Dutertre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Delobel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bruno%22%2C%22lastName%22%3A%22Marchou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Frederic%22%2C%22lastName%22%3A%22Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Martin-Blondel%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22ao%5Cu00fbt%201%2C%202019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.medmal.2019.03.002%22%2C%22ISSN%22%3A%220399-077X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0399077X17308909%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A53%3A52Z%22%7D%7D%2C%7B%22key%22%3A%22MUWNAJR6%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-01%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Jaffr%26%23xE9%3B%2C%20J.%2C%20Bernard%2C%20C.%2C%20Brossier%2C%20F.%2C%20El%20Helali%2C%20N.%2C%20Chadelat%2C%20K.%2C%20Thouvenin%2C%20G.%2C%20Dautzenberg%2C%20B.%2C%20Henry%2C%20B.%2C%20Jaspard%2C%20M.%2C%20Guillot%2C%20H.%2C%20Pourcher%2C%20V.%2C%20Le%20D%26%23xFB%3B%2C%20D.%2C%20Marigot-Outtandy%2C%20D.%2C%20Mougari%2C%20F.%2C%20Raskine%2C%20L.%2C%20Rivoire%2C%20B.%2C%20Andrejak%2C%20C.%2C%20Jarlier%2C%20V.%2C%20Aubry%2C%20A.%2C%20Robert%2C%20J.%2C%20Frechet-Jachym%2C%20M.%20and%20Veziris%2C%20N.%20%282019%29.%20%3Cb%3EMultidisciplinary%20advisory%20teams%20to%20manage%20multidrug-resistant%20tuberculosis%3A%20the%20example%20of%20the%20French%20Consilium%3C%5C%2Fb%3E.%20The%20International%20Journal%20of%20Tuberculosis%20and%20Lung%20Disease%20%3Ci%3E23%3C%5C%2Fi%3E%2C%201050%26%23x2013%3B1054%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0779%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0779%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Multidisciplinary%20advisory%20teams%20to%20manage%20multidrug-resistant%20tuberculosis%3A%20the%20example%20of%20the%20French%20Consilium%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Jaffr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22El%20Helali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Chadelat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Thouvenin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Dautzenberg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Henry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Jaspard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%22%2C%22lastName%22%3A%22Guillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Pourcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Le%20D%5Cu00fb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22D.%22%2C%22lastName%22%3A%22Marigot-Outtandy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B.%22%2C%22lastName%22%3A%22Rivoire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Andrejak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V.%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22A.%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Frechet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%5D%2C%22abstractNote%22%3A%22SETTING%3A%20The%20World%20Health%20Organization%20%28WHO%29%20recommends%20that%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20treatment%20should%20be%20managed%20in%20collaboration%20with%20multidisciplinary%20advisory%20committees%20%28consilia%29.%20A%20formal%20national%20Consilium%20has%20been%20established%20in%20France%20since%202005%20to%5Cnprovide%20a%20centralised%20advisory%20service%20for%20clinicians%20managing%20MDR-TB%20and%20extensively%20drug-resistant%20%28XDR-TB%29%20cases.%5CnOBJECTIVE%3A%20Review%20the%20activity%20of%20the%20French%20TB%20Consilium%20since%20its%20establishment.%5CnDESIGN%3A%20Retrospective%20description%20and%20analysis%20of%20the%20activity%20of%20the%5CnFrench%20TB%20Consilium.%5CnRESULTS%3A%20Between%202005%20and%202016%2C%20786%20TB%20cases%20or%20contacts%20of%20TB%20cases%20were%20presented%20at%20the%20French%20TB%20Consilium%2C%20including%20respectively%2042%25%20and%2079%25%20of%20all%20the%20MDR-TB%20and%20XDR-TB%20cases%20notified%20in%20France%20during%20this%20period.%20Treatment%20regimens%20including%20bedaquiline%5Cnand%5C%2For%20delamanid%20were%20recommended%20for%2042%25%20of%20the%20cases%20presented%20at%20the%20French%20TB%20Consilium%20since%202009.%20Patients%20were%20more%20likely%20to%20be%20presented%20at%20the%20French%20TB%20Consilium%20if%20they%20were%20born%20in%20the%20WHO%20Europe%20Region%2C%20had%20XDR-TB%2C%20were%20diagnosed%20in%20the%20Paris%20region%2C%20or%20had%20resistance%20to%20additional%5Cndrugs%20than%20those%20defining%20XDR-TB.%5CnCONCLUSION%3A%20The%20French%20TB%20Consilium%20helped%20supervise%20appropriate%20management%20of%20MDR%5C%2FXDR-TB%20cases%20and%20facilitated%20implementation%20of%20new%20drugs%20for%20MDR%5C%2FXDR-TB%20treatment.%22%2C%22date%22%3A%222019-10-01%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.18.0779%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A58%3A34Z%22%7D%7D%2C%7B%22key%22%3A%22A7PIAKJM%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Guglielmetti%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGuglielmetti%2C%20L.%2C%20Sougakoff%2C%20W.%2C%20Maitre%2C%20T.%2C%20Brossier%2C%20F.%2C%20Jarlier%2C%20V.%2C%20Robert%2C%20J.%2C%20Veziris%2C%20N.%20and%20Aubry%2C%20A.%20%282019%29.%20%3Cb%3EPoor%20Performance%20of%20Rapid%20Molecular%20Tests%20to%20Define%20Eligibility%20for%20the%20Shortcourse%20Multidrug-resistant%20Tuberculosis%20Regimen%3C%5C%2Fb%3E.%20Clinical%20Infectious%20Diseases%20%3Ci%3E68%3C%5C%2Fi%3E%2C%201410%26%23x2013%3B1411%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciy808%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciy808%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Poor%20Performance%20of%20Rapid%20Molecular%20Tests%20to%20Define%20Eligibility%20for%20the%20Shortcourse%20Multidrug-resistant%20Tuberculosis%20Regimen%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wladimir%22%2C%22lastName%22%3A%22Sougakoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Maitre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Brossier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Jarlier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%5D%2C%22abstractNote%22%3A%22The%20World%20Health%20Organization%20recommends%20shortcourse%20regimen%20%28SCR%29%20to%20treat%20multidrug%20resistant%20tuberculosis%20for%20patients%20with%20strains%20susceptible%20by%20line-probe%20assays%20%28LPAs%29%20to%20second-line%20drugs.%20Our%20retrospective%20study%20shows%20LPAs%20have%20suboptimal%20specificity%20in%20predicting%20eligibility%20for%20SCR%3B%20a%20quarter%20of%20eligible%20patients%20would%20receive%20inadequate%20therapy%20with%20SCR.%22%2C%22date%22%3A%22avril%208%2C%202019%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fcid%5C%2Fciy808%22%2C%22ISSN%22%3A%221058-4838%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fcid%5C%2Fciy808%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A57%3A13Z%22%7D%7D%2C%7B%22key%22%3A%2287NFBEBI%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Mbuagbaw%20et%20al.%22%2C%22parsedDate%22%3A%222019-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMbuagbaw%2C%20L.%2C%20Guglielmetti%2C%20L.%2C%20Hewison%2C%20C.%2C%20Bakare%2C%20N.%2C%20Bastard%2C%20M.%2C%20Caumes%2C%20E.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Robert%2C%20J.%2C%20Veziris%2C%20N.%2C%20Khachatryan%2C%20N.%2C%20Kotrikadze%2C%20T.%2C%20Hayrapetyan%2C%20A.%2C%20Avaliani%2C%20Z.%2C%20Sch%26%23xFC%3Bnemann%2C%20H.%20J.%20and%20Lienhardt%2C%20C.%20%282019%29.%20%3Cb%3EOutcomes%20of%20Bedaquiline%20Treatment%20in%20Patients%20with%20Multidrug-Resistant%20Tuberculosis%3C%5C%2Fb%3E.%20Emerg%20Infect%20Dis%20%3Ci%3E25%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2505.181823%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3201%5C%2Feid2505.181823%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcomes%20of%20Bedaquiline%20Treatment%20in%20Patients%20with%20Multidrug-Resistant%20Tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lawrence%22%2C%22lastName%22%3A%22Mbuagbaw%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Hewison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nyasha%22%2C%22lastName%22%3A%22Bakare%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Bastard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Caumes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Naira%22%2C%22lastName%22%3A%22Khachatryan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tinatin%22%2C%22lastName%22%3A%22Kotrikadze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armen%22%2C%22lastName%22%3A%22Hayrapetyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zaza%22%2C%22lastName%22%3A%22Avaliani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Holger%20J.%22%2C%22lastName%22%3A%22Sch%5Cu00fcnemann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Lienhardt%22%7D%5D%2C%22abstractNote%22%3A%22Bedaquiline%20in%20Patients%20with%20MDR%20TB%22%2C%22date%22%3A%22May%202019%22%2C%22language%22%3A%22en-us%22%2C%22DOI%22%3A%2210.3201%5C%2Feid2505.181823%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwwwnc.cdc.gov%5C%2Feid%5C%2Farticle%5C%2F25%5C%2F5%5C%2F18-1823_article%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-10T21%3A17%3A11Z%22%7D%7D%2C%7B%22key%22%3A%22I5X7JB7H%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Perrineau%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPerrineau%2C%20S.%2C%20Lach%26%23xE2%3Btre%2C%20M.%2C%20L%26%23xEA%3B%2C%20M.%20P.%2C%20Rioux%2C%20C.%2C%20Loubet%2C%20P.%2C%20Fr%26%23xE9%3Bchet-Jachym%2C%20M.%2C%20Gonzales%2C%20M.%20C.%2C%20Grall%2C%20N.%2C%20Bouvet%2C%20E.%2C%20Veziris%2C%20N.%2C%20Yazdanpanah%2C%20Y.%20and%20Peytavin%2C%20G.%20%282019%29.%20%3Cb%3ELong-term%20plasma%20pharmacokinetics%20of%20bedaquiline%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%3C%5C%2Fb%3E.%20Int%20J%20Tuberc%20Lung%20Dis%20%3Ci%3E23%3C%5C%2Fi%3E%2C%2099%26%23x2013%3B104%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0042%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fijtld.18.0042%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20plasma%20pharmacokinetics%20of%20bedaquiline%20for%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Perrineau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Lach%5Cu00e2tre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20P.%22%2C%22lastName%22%3A%22L%5Cu00ea%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Rioux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Loubet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%22%2C%22lastName%22%3A%22Fr%5Cu00e9chet-Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20Cervantes%22%2C%22lastName%22%3A%22Gonzales%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Grall%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Bouvet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22N.%22%2C%22lastName%22%3A%22Veziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Y.%22%2C%22lastName%22%3A%22Yazdanpanah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G.%22%2C%22lastName%22%3A%22Peytavin%22%7D%5D%2C%22abstractNote%22%3A%22SETTING%3A%20Bedaquiline%20%28BDQ%29%20has%20been%20approved%20for%20the%20treatment%20of%20multidrug-%20and%20extensively%20drug-resistant%20tuberculosis%20%28MDR%5C%2FXDR-TB%29.%20For%20many%20patients%20treatment%20is%20prolonged%20beyond%20the%20recommended%206%20months.%20The%20long-term%20pharmacokinetics%20of%20BDQ%20have%20yet%20to%20be%20elucidated.%5CnOBJECTIVE%3A%20To%20evaluate%20plasma%20concentrations%20of%20BDQ%20during%20treatment%20and%20its%20elimination%20after%20treatment%20discontinuation.%5CnDESIGN%3A%20This%20was%20a%20retrospective%20study%20conducted%20in%20two%20units%20in%20France%20that%20provide%20treatment%20for%20MDR%5C%2FXDR-TB.%20Sociodemographic%2C%20clinical%2C%20biological%20and%20therapeutic%20parameters%20were%20collected%20from%20patients%20currently%20or%20formerly%20treated%20with%20BDQ.%20Plasma%20concentrations%20of%20BDQ%20and%20its%20active%20M2%20%28N-desmethyl%29%20metabolite%20were%20determined%20using%20ultra-performance%20liquid%20chromatography%20with%20tandem%20mass%20spectrometry.%5CnRESULTS%3A%20Thirteen%20patients%20were%20recruited%20%2835%20samples%29%3A%2010%20%2831%20samples%29%20during%20BDQ%20treatment%20and%203%20%284%20samples%29%20after%20BDQ%20discontinuation.%20The%20median%20duration%20of%20treatment%20with%20BDQ%20was%2011%20months%20%28interquartile%20range%20%5BIQR%5D%208-14%29.%20During%20treatment%2C%20the%20median%20plasma%20BDQ%20concentrations%20and%20M2%20were%20respectively%201264%20ng%5C%2Fml%20%28IQR%20910-2244%29%20and%20252%20ng%5C%2Fml%20%28IQR%20134-290%29.%20In%20one%20patient%2C%20BDQ%20was%20detected%20in%20the%20plasma%20200%20days%20after%20treatment%20discontinuation%20%28528%20ng%5C%2Fml%29.%5CnCONCLUSION%3A%20BDQ%20and%20M2%20plasma%20concentrations%20were%20consistent%20with%20good%20drug%20efficacy%5C%2Fsafety%20profiles%2C%20suggesting%20good%20treatment%20adherence%20with%20no%20relevant%20drug%20interactions.%20The%20long-term%20plasma%20detectability%20of%20BDQ%20after%20treatment%20discontinuation%20may%20raise%20the%20spectre%20of%20the%20emergence%20of%20resistance.%22%2C%22date%22%3A%22Jan%2001%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.5588%5C%2Fijtld.18.0042%22%2C%22ISSN%22%3A%221815-7920%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A36%3A48Z%22%7D%7D%2C%7B%22key%22%3A%225FET4T2Q%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Petrella%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPetrella%2C%20S.%2C%20Capton%2C%20E.%2C%20Raynal%2C%20B.%2C%20Giffard%2C%20C.%2C%20Thureau%2C%20A.%2C%20Bonnet%26%23xE9%3B%2C%20F.%2C%20Alzari%2C%20P.%20M.%2C%20Aubry%2C%20A.%20and%20Mayer%2C%20C.%20%282019%29.%20%3Cb%3EOverall%20Structures%20of%20Mycobacterium%20tuberculosis%20DNA%20Gyrase%20Reveal%20the%20Role%20of%20a%20Corynebacteriales%20GyrB-Specific%20Insert%20in%20ATPase%20Activity%3C%5C%2Fb%3E.%20Structure%20%3Ci%3E27%3C%5C%2Fi%3E%2C%20579-589.e5%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.str.2019.01.004%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.str.2019.01.004%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Overall%20Structures%20of%20Mycobacterium%20tuberculosis%20DNA%20Gyrase%20Reveal%20the%20Role%20of%20a%20Corynebacteriales%20GyrB-Specific%20Insert%20in%20ATPase%20Activity%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Petrella%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Capton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bertrand%22%2C%22lastName%22%3A%22Raynal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Giffard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Thureau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Bonnet%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pedro%20M.%22%2C%22lastName%22%3A%22Alzari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandra%22%2C%22lastName%22%3A%22Aubry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudine%22%2C%22lastName%22%3A%22Mayer%22%7D%5D%2C%22abstractNote%22%3A%22Despite%20sharing%20common%20features%2C%20previous%20studies%20have%20shown%20that%20gyrases%20from%20different%20species%20have%20been%20modified%20throughout%20evolution%20to%20modulate%20their%20properties.%20Here%2C%20we%20report%20two%20crystal%20structures%20of%20Mycobacterium%20tuberculosis%20DNA%20gyrase%2C%20an%20apo%20and%20AMPPNP-bound%20form%20at%202.6-%5Cu00c5%20and%203.3-%5Cu00c5%20resolution%2C%20respectively.%20These%20structures%20provide%20high-resolution%20structural%20data%20on%20the%20quaternary%20organization%20and%20interdomain%20connections%20of%20a%20gyrase%20%28full-length%20GyrB-GyrA57%292%20thus%20providing%20crucial%20inputs%20on%20this%20essential%20drug%20target.%20Together%20with%20small-angle%20X-ray%20scattering%20studies%2C%20they%20revealed%20an%20%5Cu201cextremely%20open%5Cu201d%20N-gate%20state%2C%20which%20persists%20even%20in%20the%20DNA-free%20gyrase-AMPPNP%20complex%20and%20an%20unexpected%20connection%20between%20the%20ATPase%20and%20cleavage%20core%20domains%20mediated%20by%20two%20Corynebacteriales-specific%20motifs%2C%20respectively%20the%20C-loop%20and%20DEEE-loop.%20We%20show%20that%20the%5Cu00a0C-loop%20participates%20in%20the%20stabilization%20of%20this%20open%20conformation%2C%20explaining%20why%20this%20gyrase%20has%20a%20lower%20ATPase%20activity.%20Our%20results%20image%20a%20conformational%20state%20which%20might%20be%20targeted%20for%20drug%20discovery.%22%2C%22date%22%3A%22avril%202%2C%202019%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.str.2019.01.004%22%2C%22ISSN%22%3A%220969-2126%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.sciencedirect.com%5C%2Fscience%5C%2Farticle%5C%2Fpii%5C%2FS0969212619300048%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T15%3A57%3A01Z%22%7D%7D%2C%7B%22key%22%3A%226TL8VMRR%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rodriguez%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-21%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERodriguez%2C%20C.%20A.%2C%20Brooks%2C%20M.%20B.%2C%20Guglielmetti%2C%20L.%2C%20Hewison%2C%20C.%2C%20Jachym%2C%20M.%20F.%2C%20Lessem%2C%20E.%2C%20Varaine%2C%20F.%20and%20Mitnick%2C%20C.%20D.%20%282019%29.%20%3Cb%3EBarriers%20and%20facilitators%20to%20early%20access%20of%20bedaquiline%20and%20delamanid%20for%20MDR-TB%3A%20a%20mixed-methods%20study%3C%5C%2Fb%3E.%20Public%20Health%20Action%20%3Ci%3E9%3C%5C%2Fi%3E%2C%2032%26%23x2013%3B41%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fpha.18.0078%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.5588%5C%2Fpha.18.0078%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Barriers%20and%20facilitators%20to%20early%20access%20of%20bedaquiline%20and%20delamanid%20for%20MDR-TB%3A%20a%20mixed-methods%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20A.%22%2C%22lastName%22%3A%22Rodriguez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20B.%22%2C%22lastName%22%3A%22Brooks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%22%2C%22lastName%22%3A%22Hewison%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M.%20F.%22%2C%22lastName%22%3A%22Jachym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Lessem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F.%22%2C%22lastName%22%3A%22Varaine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C.%20D.%22%2C%22lastName%22%3A%22Mitnick%22%7D%5D%2C%22abstractNote%22%3A%22Setting%3A%20Phase%20II%20trials%20for%20bedaquiline%20%28BDQ%29%20and%20delamanid%20%28DLM%29%20were%20completed%20by%202011%20and%20the%20drugs%20were%20approved%20by%20stringent%20regulatory%20authorities%20for%20the%20treatment%20of%20multidrug-resistant%20tuberculosis%20%28MDR-TB%29%20between%202012%20and%202014.%20Manufacturers%20established%20%5Cu2018early%5Cnaccess%5Cu2019%20mechanisms%20to%20provide%20drugs%20before%20local%20registration.%5CnObjective%3A%20To%20inform%20improvements%20in%20early%20access%2C%20we%20explored%20experiences%20of%20providers%20and%20advocates%20in%20accessing%20BDQ%20and%20DLM%20before%20the%20end%20of%202015%20using%20a%20mixed-methods%20design.%5CnDesign%3A%20We%20examined%20barriers%5Cnand%20facilitators%20to%20early%20access%20through%20an%20electronic%20survey.%20Barriers%20and%20facilitators%20were%20classified%20as%20occurring%20at%20the%20manufacturer-%20or%20country-level.%20We%20identified%20themes%20using%20inductive%20content%20analysis%20and%20illustrated%20themes%20through%20case%20studies.%5CnResults%3A%20We%20analysed%2041%5Cnsurvey%20responses%20from%2036%20respondents%20reporting%20on%2022%20countries%3B%20early%20access%20was%20attempted%20in%2030%20%2873%25%29%20survey%20responses.%20Eligibility%20restrictions%20%2811%5C%2F30%2C%2037%25%29%20and%20complicated%20and%20slow%20processes%20%288%5C%2F30%2C%2027%25%29%20were%20manufacturer-level%20barriers%3B%20access%20to%20companion%20drugs%20%2810%2C%2033%25%29%20and%20importation%5Cndifficulties%20%284%2C%2013%25%29%20were%20country-level%20barriers.%20Previous%20experience%20with%20manufacturer%20%283%5C%2F30%2C%2010%25%29%20and%20country%20processes%20%282%5C%2F30%2C%207%25%29%20facilitated%20access.%20Eight%20case%20studies%20show%20the%20human%20impact%20of%20barriers%20and%20facilitators.%5CnConclusion%3A%20Manufacturers%20and%20countries%20should%20develop%5Cntransparent%20processes%20to%20permit%20early%20access%2C%20particularly%20for%20diseases%20that%20largely%20affect%20the%20poor%2C%20such%20as%20MDR-TB.%20Developers%20should%20plan%20for%20this%20need%20and%20rapidly%20register%20drugs%20with%20proven%20benefit%2C%20prioritizing%20high-burden%20settings.%22%2C%22date%22%3A%222019-03-21%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.5588%5C%2Fpha.18.0078%22%2C%22ISSN%22%3A%22%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T16%3A01%3A12Z%22%7D%7D%2C%7B%22key%22%3A%225ARZ5CMY%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rollet-Cohen%20et%20al.%22%2C%22parsedDate%22%3A%222019-03-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERollet-Cohen%2C%20V.%2C%20Roux%2C%20A.-L.%2C%20Bourgeois%2C%20M.%20L.%2C%20Sapriel%2C%20G.%2C%20Bahri%2C%20M.%20E.%2C%20Jais%2C%20J.-P.%2C%20Heym%2C%20B.%2C%20Mougari%2C%20F.%2C%20Raskine%2C%20L.%2C%20V%26%23xE9%3Bziris%2C%20N.%2C%20Gaillard%2C%20J.-L.%20and%20Sermet-Gaudelus%2C%20I.%20%282019%29.%20%3Cb%3EMycobacterium%20bolletii%20lung%20disease%20in%20cystic%20fibrosis%3C%5C%2Fb%3E.%20CHEST%20%3Ci%3E0%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.chest.2019.03.019%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.chest.2019.03.019%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Mycobacterium%20bolletii%20lung%20disease%20in%20cystic%20fibrosis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Rollet-Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Roux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%20Le%22%2C%22lastName%22%3A%22Bourgeois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Sapriel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manele%20El%22%2C%22lastName%22%3A%22Bahri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Jais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beate%22%2C%22lastName%22%3A%22Heym%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faiza%22%2C%22lastName%22%3A%22Mougari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Raskine%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22V%5Cu00e9ziris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Louis%22%2C%22lastName%22%3A%22Gaillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Sermet-Gaudelus%22%7D%5D%2C%22abstractNote%22%3A%22%3Ch2%3EAbstract%3C%5C%2Fh2%3E%3Ch3%3EBackground%3C%5C%2Fh3%3E%3Cp%3EThe%20cystic%20fibrosis%20%28CF%29%20pathogen%2C%20%3Ci%3EMycobacterium%20abscessus%3C%5C%2Fi%3E%20complex%2C%20covers%20three%20%5C%22subspecies%5C%22%3A%20%5C%22%3Ci%3EM.%20abscessus%5C%22%2C%20%5C%22M.%20massiliense%5C%22%2C%3C%5C%2Fi%3E%20and%20%5C%22%3Ci%3EM.%20bolletii%3C%5C%2Fi%3E%5C%22.%20There%20are%20no%20clinical%20outcome%20data%20concerning%20%3Ci%3EM.%20bolletii%3C%5C%2Fi%3E.%3C%5C%2Fp%3E%3Cp%3EOur%20aim%20was%20to%20characterize%20%3Ci%3EM.%20bolletii%3C%5C%2Fi%3E%20lung%20infections%20in%20CF%20patients.%3C%5C%2Fp%3E%3Ch3%3EMethods%3C%5C%2Fh3%3E%3Cp%3EWe%20included%20cases%20of%20%3Ci%3EM.%20bolletii%3C%5C%2Fi%3E%20lung%20infection%20recorded%20between%201994%20and%202012%20in%20France.%20Data%20were%20collected%20from%20the%20CF%20registry%2C%20medical%20records%2C%20and%20questionnaires%20submitted%20to%20the%20CF%20primary%20physician.%20Strains%20were%20typed%20by%20Multilocus%20Sequence%20Typing%20%28MLST%29%20analysis.%3C%5C%2Fp%3E%3Ch3%3EResults%3C%5C%2Fh3%3E%3Cp%3EFifteen%20cases%20were%20identified%20in%20nine%20CF%20centers.%20Nine%20patients%20%2860%25%29%20presented%20with%20nontuberculous%20mycobacteria%20pulmonary%20disease%20%28NTM-PD%29.%20Follow%20up%20of%2013%20patients%20showed%20a%20trend%20to%20a%20more%20rapid%20decline%20in%20FEV%3Csub%3E1%3C%5C%2Fsub%3E%20the%20first%20year%20of%20colonization%20%28-9.4%25%20%2819.3%29%29%20in%20comparison%20to%20non-infected%20controls%20%28-2.3%25%20%2812.1%29%3B%20%3Ci%3Ep%3C%5C%2Fi%3E%3D0.16%29.%20Twelve%20patients%20were%20treated%2C%20and%2011%20received%20oral%20macrolides.%20Treatment-induced%20eradication%20occured%20in%205%20patients%20%2841.7%25%29.%20Four%20patients%20died%20%2826.7%25%29%2C%20including%201%20case%20of%20fatal%20NTM-PD.%20Inducible%20macrolide%20resistance%20was%20demonstrated%20in%20all%20strains.%20Patients%20always%20harbored%20unique%20strains..%3C%5C%2Fp%3E%3Ch3%3EConclusion%3C%5C%2Fh3%3E%3Cp%3EOur%20study%20reports%20the%20largest%20study%20cohort%20of%20CF%20patients%20infected%20with%20%3Ci%3EM.%20bolletii.%20M%20bolletii%3C%5C%2Fi%3E%20infection%20affects%20both%20children%20and%20young%20adults%2C%20is%20most%20often%20symptomatic%20and%20may%20be%20fatal.%20Macrolide-based%20therapies%20have%20poor%20effectiveness.%20There%20is%20no%20evidence%20of%20patient-to-patient%20transmission.%3C%5C%2Fp%3E%22%2C%22date%22%3A%222019%5C%2F03%5C%2F29%22%2C%22language%22%3A%22English%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.chest.2019.03.019%22%2C%22ISSN%22%3A%220012-3692%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fjournal.chestnet.org%5C%2Farticle%5C%2FS0012-3692%2819%2930747-0%5C%2Fabstract%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222019-04-03T22%3A23%3A42Z%22%7D%7D%2C%7B%22key%22%3A%226CF69V4U%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sane%20Schepisi%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESane%20Schepisi%2C%20M.%2C%20Navarra%2C%20A.%2C%20Altet%20Gomez%2C%20M.%20N.%2C%20Dudnyk%2C%20A.%2C%20Dyrhol-Riise%2C%20A.%20M.%2C%20Esteban%2C%20J.%2C%20Giorgetti%2C%20P.%20F.%2C%20Gualano%2C%20G.%2C%20Guglielmetti%2C%20L.%2C%20Heyckendorf%2C%20J.%2C%20Kaluzhenina%2C%20A.%2C%20Lange%2C%20B.%2C%20Lange%2C%20C.%2C%20Manika%2C%20K.%2C%20Miah%2C%20J.%2C%20Nanovic%2C%20Z.%2C%20Pontali%2C%20E.%2C%20Prego%2C%20M.%20R.%2C%20Solovic%2C%20I.%2C%20Tiberi%2C%20S.%2C%20Palmieri%2C%20F.%20and%20Girardi%2C%20E.%20%282019%29.%20%3Cb%3EBurden%20and%20Characteristics%20of%20the%20Comorbidity%20Tuberculosis%26%23x2014%3BDiabetes%20in%20Europe%3A%20TBnet%20Prevalence%20Survey%20and%20Case-Control%20Study%3C%5C%2Fb%3E.%20Open%20Forum%20Infectious%20Diseases%20%3Ci%3E6%3C%5C%2Fi%3E%2C%20ofy337%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofy337%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofy337%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Burden%20and%20Characteristics%20of%20the%20Comorbidity%20Tuberculosis%5Cu2014Diabetes%20in%20Europe%3A%20TBnet%20Prevalence%20Survey%20and%20Case-Control%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%22%2C%22lastName%22%3A%22Sane%20Schepisi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Assunta%22%2C%22lastName%22%3A%22Navarra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%20Nieves%22%2C%22lastName%22%3A%22Altet%20Gomez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrii%22%2C%22lastName%22%3A%22Dudnyk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%20Margarita%22%2C%22lastName%22%3A%22Dyrhol-Riise%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaime%22%2C%22lastName%22%3A%22Esteban%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pier%20Francesco%22%2C%22lastName%22%3A%22Giorgetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gina%22%2C%22lastName%22%3A%22Gualano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Heyckendorf%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anna%22%2C%22lastName%22%3A%22Kaluzhenina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berit%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katerina%22%2C%22lastName%22%3A%22Manika%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jalal%22%2C%22lastName%22%3A%22Miah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zorica%22%2C%22lastName%22%3A%22Nanovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emanuele%22%2C%22lastName%22%3A%22Pontali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Monica%20Rios%22%2C%22lastName%22%3A%22Prego%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ivan%22%2C%22lastName%22%3A%22Solovic%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Simon%22%2C%22lastName%22%3A%22Tiberi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrizio%22%2C%22lastName%22%3A%22Palmieri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Girardi%22%7D%5D%2C%22abstractNote%22%3A%22The%20growing%20burden%20of%20diabetes%20mellitus%20%28DM%29%20is%20posing%20a%20threat%20to%20global%20tuberculosis%20%28TB%29%20control.%20DM%20triples%20the%20risk%20of%20developing%20TB%2C%20modifies%20the%20presenting%20features%20of%20pulmonary%20TB%2C%20and%20worsens%20TB%20treatment%20outcomes.%20We%20aimed%20to%20analyze%20the%20prevalence%20of%20DM%20among%20TB%20patients%20and%20to%20describe%20the%20characteristics%20and%20clinical%20presentation%20of%20TB-DM%20patients%20in%20Europe.We%20performed%20a%20cross-sectional%20survey%20on%20the%20prevalence%20of%20DM%20among%20consecutively%20diagnosed%20adult%20TB%20patients%20in%2011%20European%20TB%20referral%20centers%20located%20in%20France%2C%20Germany%2C%20Greece%2C%20Italy%2C%20Russia%2C%20Slovakia%2C%20Spain%2C%20and%20the%20United%20Kingdom%20over%20the%20period%202007%5Cu20132015.%20We%20also%20selected%20DM-TB%20cases%20and%20TB%20only%20controls%20with%20a%201%3A3%20ratio%20to%20perform%20a%20case-control%20analysis%2C%20including%20patients%20selected%20from%20the%20countries%20mentioned%20above%20plus%20Norway%20and%20Ukraine.Among%203143%20TB%20enrolled%20patients%2C%20DM%20prevalence%20overall%20was%2010.7%25%20and%20ranged%20from%204.4%25%20in%20Greece%20to%2028.5%25%20in%20the%20United%20Kingdom.%20Patients%5Cu2019%20median%20ages%20ranged%20from%2036%20to%2049%20years%2C%20and%20all%20centers%20had%20%26gt%3B60%25%20males%3B%20the%20proportion%20of%20foreign-born%20patients%20varied%20widely%20across%20sites.%20In%20the%20case-control%20study%2C%20DM%20was%20independently%20associated%20with%20older%20age%20and%2C%20among%20older%20patients%2C%20with%20being%20foreign-born.%20Among%20patients%20with%20pulmonary%20involvement%2C%20cavities%20on%20chest%20imaging%20were%20more%20frequently%20observed%20among%20those%20with%20DM.Diabetes%20mellitus%20represents%20a%20challenge%20for%20TB%20control%20in%20Europe%2C%20especially%20in%20foreign-born%20and%20in%20elderly%20patients.%20Specific%20screening%20strategies%20should%20be%20evaluated.%22%2C%22date%22%3A%22janvier%201%2C%202019%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.1093%5C%2Fofid%5C%2Fofy337%22%2C%22ISSN%22%3A%222328-8957%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Fofid%5C%2Fofy337%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-02-25T16%3A00%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22TZ3ECBUW%22%2C%22library%22%3A%7B%22id%22%3A1368488%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22van%20Leth%20et%20al.%22%2C%22parsedDate%22%3A%222019-01-01%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3Evan%20Leth%2C%20F.%2C%20Brinkmann%2C%20F.%2C%20Cirillo%2C%20D.%20M.%2C%20Dheda%2C%20K.%2C%20Duarte%2C%20R.%2C%20Guglielmetti%2C%20L.%2C%20Kuksa%2C%20L.%2C%20Lange%2C%20C.%2C%20Mitnick%2C%20C.%2C%20Skrahina%2C%20A.%2C%20Zaman%2C%20K.%20and%20Bothamley%2C%20G.%20%282019%29.%20%3Cb%3EThe%20Tuberculosis%20Network%20European%20Trials%20group%20%28TBnet%29%20ERS%20Clinical%20Research%20Collaboration%3A%20addressing%20drug-resistant%20tuberculosis%20through%20European%20cooperation%3C%5C%2Fb%3E.%20European%20Respiratory%20Journal%20%3Ci%3E53%3C%5C%2Fi%3E%2C%20%3Ca%20target%3D%27_blank%27%20href%3D%27http%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.02089-2018%27%3Ehttp%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1183%5C%2F13993003.02089-2018%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Tuberculosis%20Network%20European%20Trials%20group%20%28TBnet%29%20ERS%20Clinical%20Research%20Collaboration%3A%20addressing%20drug-resistant%20tuberculosis%20through%20European%20cooperation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%22%2C%22lastName%22%3A%22van%20Leth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Folke%22%2C%22lastName%22%3A%22Brinkmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20M.%22%2C%22lastName%22%3A%22Cirillo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Keertan%22%2C%22lastName%22%3A%22Dheda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raquel%22%2C%22lastName%22%3A%22Duarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Guglielmetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liga%22%2C%22lastName%22%3A%22Kuksa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22Lange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Mitnick%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alena%22%2C%22lastName%22%3A%22Skrahina%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Khalequ%22%2C%22lastName%22%3A%22Zaman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Graham%22%2C%22lastName%22%3A%22Bothamley%22%7D%5D%2C%22abstractNote%22%3A%22Tweetable%20abstract%20%40ERSpublications%5Cnclick%20to%20tweetThe%20Tuberculosis%20Network%20European%20Trials%20group%20%28TBnet%29%20continues%20the%20successful%20ERS%20Clinical%20Research%20Collaboration%20on%20drug-resistant%20tuberculosis%20http%3A%5C%2F%5C%2Fow.ly%5C%2FgGH330mHrDa%22%2C%22date%22%3A%222019%5C%2F01%5C%2F01%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1183%5C%2F13993003.02089-2018%22%2C%22ISSN%22%3A%220903-1936%2C%201399-3003%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Ferj.ersjournals.com%5C%2Fcontent%5C%2F53%5C%2F1%5C%2F1802089%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222022-03-12T08%3A15%3A47Z%22%7D%7D%5D%7D
Andrés, M., Werf, M. J. van der, Ködmön, C., Albrecht, S., Haas, W., Fiebig, L. and Group, S. study (2019). Molecular and genomic typing for tuberculosis surveillance: A survey study in 26 European countries. PLOS ONE 14, e0210080, http://doi.org/10.1371/journal.pone.0210080.
Aubry, A. and Veziris, N. (2019). Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections. Am J Respir Crit Care Med 200, 1072–1073, http://doi.org/10.1164/rccm.201905-0965LE.
Baron, V., Forfait, C., Colot, J., Carzola, C., Descloux, E., Cauchoix, B., Cambau, E., Gaumery, J., Grangeon, J. and Klement, E. (2019). Épidémiologie de la lèpre en Nouvelle-Calédonie de 1983 à 2017. BEH 400–405, URL: https://www.santepubliquefrance.fr/import/epidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017 [Accessed February 2022].
Bouziane, F., Allem, R., Sebaihia, M., Kumanski, S., Mougari, F., Sougakoff, W., Raskine, L., Yala, D. and Cambau, E. (2019). First genetic characterisation of multidrug-resistant Mycobacterium tuberculosis isolates from Algeria. Journal of Global Antimicrobial Resistance 19, 301–307, http://doi.org/10.1016/j.jgar.2019.05.010.
Daniau, C., Lecorché, E., Mougari, F. and et al. (2019). Infections invasives à Mycobacterium chimaera en chirurgie cardiaque et évaluation des pratiques autour des matériels de circulation extracorporelle. Hygienes 27, 351–359, http://doi.org/10.25329/hy_xxvii_6-1.
Decalonne, M., Lecorche, E., Hau, E., Petiteau, A., Moreau, C., Milan, O., Lanotte, P., Mereghetti, L., Cambau, E. and van der Mee-Marquet, N. (2019). Cause Analysis of an Infection in Facelift Surgery Due to Mycobacterium chelonae. Frontiers in Medicine 6, URL: https://www.frontiersin.org/article/10.3389/fmed.2019.00243 [Accessed February 2022].
Dutertre, M., Delobel, P., Marchou, B., Boyer, J.-F., Mougari, F. and Martin-Blondel, G. (2019). Olecranon bursitis secondary to Mycobacterium europaeum infection in a patient receiving immunosuppressive drugs for rheumatoid arthritis. Médecine et Maladies Infectieuses 49, 358–359, http://doi.org/10.1016/j.medmal.2019.03.002.
Guglielmetti, L., Jaffré, J., Bernard, C., Brossier, F., El Helali, N., Chadelat, K., Thouvenin, G., Dautzenberg, B., Henry, B., Jaspard, M., Guillot, H., Pourcher, V., Le Dû, D., Marigot-Outtandy, D., Mougari, F., Raskine, L., Rivoire, B., Andrejak, C., Jarlier, V., Aubry, A., Robert, J., Frechet-Jachym, M. and Veziris, N. (2019). Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. The International Journal of Tuberculosis and Lung Disease 23, 1050–1054, http://doi.org/10.5588/ijtld.18.0779.
Guglielmetti, L., Sougakoff, W., Maitre, T., Brossier, F., Jarlier, V., Robert, J., Veziris, N. and Aubry, A. (2019). Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. Clinical Infectious Diseases 68, 1410–1411, http://doi.org/10.1093/cid/ciy808.
Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., Fréchet-Jachym, M., Robert, J., Veziris, N., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Schünemann, H. J. and Lienhardt, C. (2019). Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis 25, http://doi.org/10.3201/eid2505.181823.
Perrineau, S., Lachâtre, M., Lê, M. P., Rioux, C., Loubet, P., Fréchet-Jachym, M., Gonzales, M. C., Grall, N., Bouvet, E., Veziris, N., Yazdanpanah, Y. and Peytavin, G. (2019). Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 23, 99–104, http://doi.org/10.5588/ijtld.18.0042.
Petrella, S., Capton, E., Raynal, B., Giffard, C., Thureau, A., Bonneté, F., Alzari, P. M., Aubry, A. and Mayer, C. (2019). Overall Structures of Mycobacterium tuberculosis DNA Gyrase Reveal the Role of a Corynebacteriales GyrB-Specific Insert in ATPase Activity. Structure 27, 579-589.e5, http://doi.org/10.1016/j.str.2019.01.004.
Rodriguez, C. A., Brooks, M. B., Guglielmetti, L., Hewison, C., Jachym, M. F., Lessem, E., Varaine, F. and Mitnick, C. D. (2019). Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action 9, 32–41, http://doi.org/10.5588/pha.18.0078.
Rollet-Cohen, V., Roux, A.-L., Bourgeois, M. L., Sapriel, G., Bahri, M. E., Jais, J.-P., Heym, B., Mougari, F., Raskine, L., Véziris, N., Gaillard, J.-L. and Sermet-Gaudelus, I. (2019). Mycobacterium bolletii lung disease in cystic fibrosis. CHEST 0, http://doi.org/10.1016/j.chest.2019.03.019.
Sane Schepisi, M., Navarra, A., Altet Gomez, M. N., Dudnyk, A., Dyrhol-Riise, A. M., Esteban, J., Giorgetti, P. F., Gualano, G., Guglielmetti, L., Heyckendorf, J., Kaluzhenina, A., Lange, B., Lange, C., Manika, K., Miah, J., Nanovic, Z., Pontali, E., Prego, M. R., Solovic, I., Tiberi, S., Palmieri, F. and Girardi, E. (2019). Burden and Characteristics of the Comorbidity Tuberculosis—Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. Open Forum Infectious Diseases 6, ofy337, http://doi.org/10.1093/ofid/ofy337.
van Leth, F., Brinkmann, F., Cirillo, D. M., Dheda, K., Duarte, R., Guglielmetti, L., Kuksa, L., Lange, C., Mitnick, C., Skrahina, A., Zaman, K. and Bothamley, G. (2019). The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal 53, http://doi.org/10.1183/13993003.02089-2018.